Poland· PL-100387071

Bilomag

A ginkgoblatt product containing ginkgonis extractum siccum raffinatum et quantificatum, registered in Poland by Natur Produkt Pharma Sp. z o.o.. The same ATC class is registered in 6 of our 19 countries.

ATC N06DX02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBilomagATCN06DX02REGISTER NO.PL-100387071PACKS LISTED4CHECKEDSeptember 27, 2026

Where it is registered

Ginkgoblatt is registered in 6 of 19 countries.

Countries holding a registration under ATC N06DX02 (ginkgoblatt), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose

Ginkgoblatt · ATC N06DX02

6 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Polandprice
  • Spainprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Ginkgonis extractum siccum raffinatum et quantificatum
Manufacturer
Natur Produkt Pharma Sp. z o.o.
Country
Poland (PL)
ATC code
N06DX02
ATC class
Ginkgoblatt
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05909991388102
  • gtin
    05909991388119
  • gtin
    05909991388126
  • gtin
    05909991388133

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

22 interactions on record for ginkgoblatt.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ginkgoblatt · interactions on record

22 records

22 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Ginkgoblatt in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ginkgoblatt products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Germany · Synapsan
  • Denmark · Bio-Biloba
  • Estonia · Bio-Biloba
  • Spain · Incebral
  • France · Vitalogink
  • Croatia · Bilobil Intense
  • Hungary · Tebofortan
  • Portugal · Abolibe Forte, Biloban
  • Slovakia · Gingio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2c022ee9-cda7-4fcc-8aad-e10069a08baa
GET /v1/drugs/2c022ee9-cda7-4fcc-8aad-e10069a08baa?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "80 mg",
  "packaging": "05909991388102 ¦ OTC ¦ 130401\n20 kaps.\n05909991388119 ¦ OTC ¦ 130402\n60 kaps.\n05909991388126 ¦ OTC ¦ 130403\n90 kaps.\n05909991388133 ¦ OTC ¦ 130404\n120 kaps.",
  "substance": "Ginkgonis extractum siccum raffinatum et quantificatum 80 mg",
  "common_name": "Ginkgonis extractum siccum raffinatum et quantificatum",
  "pl_product_id": "100387071",
  "pozwolenie_nr": "25004",
  "auth_procedure": "NAR",
  "authorisation_validity": "2023-12-06"
}

See everything about ginkgoblatt.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.